May 2, 2014
Ono Pharmaceutical and Nissan Chemical Industries said on April 30 that they terminated on the same day a licensing agreement for a new thrombocytopenia agent, NIP-022/ONO-7746, due to stalled clinical studies overseas. Originated by Nissan Chemical, the compound was licensed...read more